SRGAP2C

Across TCGA pan-cancer cohorts, SRGAP2C Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SRGAP2C data layer compared with 25 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher SRGAP2C Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SRGAP2C expression acts as an unfavorable survival marker.

LIHC, PRAD, and SKCM are the cancer types where SRGAP2C Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.038	0.553	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SKCM	DFS	Median	All	0.046	0.738	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SRGAP2C–LIHC (DFS)

Open the LIHC breakdown →